# FDA Issues Four Oncology Approvals in Two Weeks in July 2026 Across Breast, Lung, Bladder, and Blood Cancers

> fda · REPORTED · 2026-07-31

July 2026 brought a dense run of FDA oncology activity, with four new cancer drug approvals landing within two weeks in the middle of the month spanning breast, lung, bladder, and hematologic malignancies. A formulation switch also gave multiple myeloma patients a subcutaneous needle-and-syringe alternative to infusion chairs, while a liver cancer combination was rejected for the third time.

About Multiple FDA Oncology Approvals: The FDA's oncology review program covers a broad range of cancer types and drug modalities, with July 2026 being one of the most active regulatory periods of the year for cancer drug approvals.

- Company: Multiple FDA Oncology Approvals
- Sector: oncology
- Primary source: https://www.targetedonc.com/view/july-2026-in-oncology-a-look-back-at-fda-approvals-and-decisions

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.